监测抗病毒药物不良事件的主动药物警戒策略比较:系统综述
该系统综述纳入36项观察性前瞻性主动药物警戒研究、IV期临床试验及干预性研究,聚焦全身抗病毒药物暴露人群。药物事件监测(DEM)是最主要策略,患者访谈是最常用数据源,研究质量18/36为良好、17/36为差。DEM似可提高检测到较高不良事件发生率可能性,需建立统一框架。
要点
- 药物事件监测是抗病毒药物主动药物警戒的主要策略。
- 患者访谈是最常用数据源,其次为病历和实验室检查。
- 研究质量参差,36项中17项质量为差。
核心结论
- 药物事件监测是主要主动药物警戒策略,使用多数据源,似可提高检测到较高不良事件发生率的可能性。
- 建立统一框架可促进不同研究和环境下更详细一致的主动药物警戒方法。
研究设计与样本
- 系统综述,检索三个电子文献数据库,纳入观察性前瞻性主动药物警戒研究、上市后安全性监测的IV期临床试验及评估主动药物警戒策略的干预性研究。
- 共纳入36项原始研究,主要使用药物事件监测,少数采用哨点站点和登记系统。
主要发现
- 人类免疫缺陷病毒(HIV)是最常见疾病,多数使用药物事件监测。
- 药物事件监测研究中,患者经历至少一种不良事件的发生率范围宽泛,多数研究使用一个或两个数据源。
- 哨点站点研究较少,两项关于丙型肝炎病毒(HCV),一项关于HIV,各依赖一个或两个数据源。
- 唯一使用登记系统的HIV治疗研究仅报告使用一个数据源。
- 患者访谈是最常见数据源,其次为病历和实验室检查。
临床怎么用
- 临床药学智能体医生在开展抗病毒药物主动药物警戒时,可优先考虑药物事件监测策略并整合患者访谈、病历和实验室检查等多数据源。
- 应关注研究设计质量,避免仅依赖单一数据源,以提高不良事件检测的全面性和可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The safety of antiviral agents in real-world clinical settings is crucial, as pre-marketing studies often do not capture all adverse events (AE). Active pharmacovigilance strategies are essential for detecting and characterising these AE comprehensively. OBJECTIVE: The aim of this study was to identify and characterise active pharmacovigilance strategies used in real-world clinical settings for patients under systemic antiviral agents, focusing on the frequency of AE and the clinical data sources used. METHODS: We conducted a systematic review by searching three electronic bibliographic databases targeting observational prospective active pharmacovigilance studies, phase IV clinical trials for post-marketing safety surveillance, and interventional studies assessing active pharmacovigilance strategies, focusing on individuals exposed to systemic antiviral agents. RESULTS: We included 36 primary studies, predominantly using Drug Event Monitoring (DEM), with a minority employing sentinel sites and registries. Human immunodeficiency virus (HIV) was the most common condition, with the majority using DEM. Within the DEM, there was a wide range of incidences of patients experiencing at least one AE, and most of these studies used one or two data sources. Sentinel site studies were less common, with two on hepatitis C virus (HCV) and one on HIV, each relying on one or two data sources. The single study using a registry focusing on HIV therapy reported using just one data source. Patient interviews were the most common data source, followed by medical records and laboratory tests. The quality of the studies was considered 'good' in 18/36, 'fair' in 1/36, and 'poor' in 17/36 studies. CONCLUSION: DEM was the predominant pharmacovigilance strategy, employing multiple data sources, and appears to increase the likelihood of detecting higher AE incidence. Establishing such a framework would facilitate a more detailed and consistent approach across different studies and settings.
引用
- Ferreira-da-Silva R, Reis-Pardal J, Pinto M, et al. A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review. Drug Saf. 2024. PMID: 39160354. doi:10.1007/s40264-024-01470-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。